Terapia
216 articole · RSS
Terapia, investitii de 100.000 dolari pentru un nou medicament
Terapia Cluj, al doilea producator de medicamente din Romania, a investit circa 100.000 de dolari pentru a iesi pe piata cu nou produs: Pentoxi Retard. Medicamentul, destinat afectiunilor ca...
Terapia: new manager, new programme
Several months after taking over Terapia Cluj-Napoca, the second-largest Romanian drugmaker, American financial group Advent International is beginning a new streamlining programme set to cu...
Terapia Cluj: alt director executiv, un nou program de restructurare
La cateva luni dupa preluarea Terapia Cluj -Napoca, al doilea producator roman de medicamente, grupul financiar american Advent International incepe un nou program de restructurare a compani...
Advent begins to invest in Terapia
Several months after taking over drugmaker Terapia Cluj-Napoca, US financial group Advent International is beginning the investments scheduled to continue the company's modernisation. Theref...
Advent incepe investitiile in Terapia
La cateva luni dupa preluarea producatorului de medicamente Terapia Cluj -Napoca, grupul financiar american Advent International incepe investitiile programate pentru continuarea modernizari...
Demisie la nivel inalt la Terapia
Dorin Toderas va renunta incepand cu 1 februarie 2004 la functia de director general al producatorului de medicamente Terapia Cluj Napoca, urmand a se dedica de a dezvolta si alte opotunitat...
Terapia general manager steps down
Dorin Toderas (photo) will step down from his general manager position at drugmaker Terapia Cluj Napoca as of February 1, 2004 and will seek to develop other business opportunities outside t...
Terapia sales steady, profit up
Terapia Cluj Napoca, Romania's second-largest drugmaker, saw profit up 30% in dollars in nine months this year, whereas turnover maintained at some $23-24 million. The company reported net p...
Terapia sales steady, profit up
Terapia Cluj Napoca, Romania's second-largest drugmaker, saw profit up 30% in dollars in nine months this year, whereas turnover maintained at some $23-24 million. The company reported net p...